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Objective. It is becoming increasingly apparent
that B cells play an important role in the pathogenesis
of rheumatoid arthritis (RA). Due to the scarcity of B
cells in RA, it has been technically difficult to function-
ally characterize B cell apoptosis in this disease. As a
necessary first step to identify candidate aberrations, we
investigated Fas-mediated signaling events in immortal-
ized peripheral blood B lymphoblastoid cell lines
(LCLs) from patients with RA and controls.
Methods. Cell death was determined by the MTS
assay, and apoptosis was detected by the TUNEL assay
and DNA laddering. Proteolytic activation of caspase 3
was determined by immunoblotting, and its enzymatic
activity was determined by a fluorometric technique.
Messenger RNA (mRNA) expression was quantified by
real-time polymerase chain reaction (PCR) analysis.
The functional role of sphingosine kinase (SPHK) was
determined by measuring its enzymatic activity, by
quantifying the levels of its product, sphingosine
1-phosphate (S1P), and by investigating the ability of
the SPHK inhibitor N,N-dimethylsphingosine and
isozyme-specific small interfering RNA (siRNA) oligo-
nucleotides to reverse signaling aberrations.
Results. LCLs from patients with RA displayed
disease-specific Fas-mediated signal transduction im-
pairment with consequent resistance to cell death. RA
LCLs displayed high constitutive SPHK activity and
increased levels of S1P. Real-time PCR analysis showed
higher SPHK-1 mRNA expression levels in RA patients
compared with paired controls. Increased SPHK-1 (but
not SPHK-2) mRNA levels were observed in synovial
tissue from RA patients. Competitive inhibitors of
SPHK reversed the resistance of RA LCLs to Fas-
induced apoptosis. Additionally, resistance to Fas-
mediated signaling was reversed by siRNA oligonucleo-
tides specific for SPHK-1 but not by oligonucleotides
specific for SPHK-2.
Conclusion. These findings demonstrate disease-
specific resistance to Fas-mediated death signaling in
patients with RA and implicate increased SPHK-1 ac-
tivity as the cause of this aberration.
Rheumatoid arthritis (RA) is a systemic disease
characterized by infiltration of inflammatory cells into
the synovium and hyperplasia of the synovial lining cells
that lead to destruction of adjacent cartilage and bone
(for review, see ref. 1). It has been previously postulated
that either aberrant apoptosis or migration of cells from
the peripheral blood into the synovial compartment may
be responsible for pathologic stockpiling of cells in the
rheumatoid pannus (2–7).
Over the past several years, interest in the patho-
genic role of B lymphocytes in RA has reemerged (for
review, see ref. 8). In addition to the realization that
antibodies do play important roles in experimental mod-
els of RA and in the human disease, there is increasing
evidence that B lymphocytes accumulate and mature in
the inflamed synovium, where they can form ectopic
germinal centers (9–11) and activate T cells (12). Addi-
tionally, experimental treatments with anti-CD20 anti-
bodies have shown promise (13) and further support the
growing consensus that B lymphocytes play an important
role in the pathogenesis of RA. The propensity of B
lymphocytes to accumulate in the synovium has been
attributed to the local trophic influence of resident
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synoviocytes (9,10). However, what the mechanisms
governing their homing to the synovium are, and
whether B cells are intrinsically resistant to programmed
cell death, are questions that are presently unanswered.
There is ample evidence that B cell Fas-mediated
cell death plays a key role in the maintenance of self
tolerance, and that failure of this mechanism can lead to
autoimmunity (for review, see ref. 14). However, due to
the marked scarcity of peripheral B lymphocytes in RA
(15,16), little is known about Fas-mediated cell death of
B lymphocytes in this disease.
In this study, we investigated the efficiency of
Fas-mediated death signaling in peripheral blood B
lymphocytes. In an attempt to overcome the scarcity of
peripheral B lymphocytes in RA, we used immortalized
lymphoblastoid cell lines (LCLs). Our data indicate that
LCLs from patients with RA are uniquely resistant to
Fas-mediated cell death. The aberration is attributable
to overactivity of sphingosine kinase 1 (SPHK-1), with
resultant overproduction of sphingosine 1-phosphate
(S1P), a sphingolipid previously shown to inhibit apo-
ptosis and to regulate lymphoid migratory pathways
(17,18).
PATIENTS AND METHODS
Study subjects. A panel of LCLs from a total of 78
individuals (23 patients with RA, 8 with systemic lupus ery-
thematosus [SLE], 10 with juvenile RA [JRA], 3 with auto-
immune thyroiditis, and 5 with insulin-dependent diabetes
mellitus [IDDM], as well as 29 healthy controls) was used in
this study. The RA group (58% women and 42% men, mean 
SD age 49.2  11.9 years) and the control group (61% women
and 39% men, mean  SD age 45  12.3 years) did not differ
demographically. The salient clinical features of the RA group
are shown in Table 1. A panel of LCLs from 10 RA-discordant
monozygotic twin pairs (7 female pairs and 3 male pairs,
mean  SD age 45.2  10.7 years) was used in some
experiments. Synovial tissues obtained during joint replace-
ment surgery in 14 patients with RA and 9 patients with
osteoarthritis (OA) were used to quantify synovial tissue
SPHK messenger RNA (mRNA) expression.
Cells and culture conditions. LCLs were prepared
from peripheral blood B cells, using a standard technique (19),
and were cultured in supplemented RPMI 1640 containing
10% heat-inactivated fetal bovine serum (Irvine Scientific,
Santa Ana, CA). In all experiments, test and control cells
were obtained from lines that had been maintained in iden-
tical tissue culture conditions, with identical cell density and
viability.
Induction of apoptosis. Fas-mediated apoptosis was
induced in LCLs by incubating 5  104 cells/well with 100
ng/ml of anti-Fas monoclonal antibody CH-11 (IgM; Medical
and Biological Laboratories, Watertown, MA) in 96-well mi-
croplates. Control mouse IgM monoclonal antibody (TEPC-
183; Sigma, St. Louis, MO) was used in equivalent concentra-
tions. Cell death was determined at different time points, using
a commercial MTS kit (Promega, Madison, WI). Microplate
wells were read using an enzyme-linked immunosorbent assay
plate reader at 490 nm.
Table 1. Clinical features of the patients with rheumatoid arthritis*
Patient/sex/
age, years Disease duration RF Nodules Erosions Therapy HLA–DRB1
1/M/62 23 years    Gold, MTX 0401/0404
2/M/46 8 years    AZA, gold, HCQ, MTX, SSZ 0401/0404
3/F/48 6 years    HCQ, MTX 0401/0404
4/F/42 6 months – – – NSAID 0401/11
5/M/44 11 years   – MTX, prednisone 0401/0404
6/F/62 33 years    AZA, gold, HCQ, MTX, SSZ 0401/0401
7/M/54 10 years    Gold 0401/15
8/F/45 7 years    MTX, NSAID 0401/17
9/M/64 16 years – –  NSAID 0101/0701
10/F/53 5 months  – – NSAID 17/17
11/F/21 14 months  – – Gold, HCQ, NSAID 0101/0404
12/M/72 19 years – –  NSAID, prednisone 0401/14
13/M/52 4 months  –  NSAID, prednisone 0101/15
14/F/34 11 years  –  NA 0401/1201
15/F/53 9 years  –  NA 0401/1104
16/M/44 NA    NA 0101/0301
17/F/NA NA NA NA NA NA 0101/1302
18/F/37 5 years    NA 0401/0401
19/F/36 6 years    NA 0404/1401
20/M/32 10 years – –  NA 0401/0701
21/F/62 13 years    NA 0401/0701
22/F/65 3 years  – – NA 0401/0401
23/M/58 6 months  – – NSAID 0405/11
* RF  rheumatoid factor; MTX  methotrexate; AZA  azathioprine; HCQ  hydroxychloroquine; SSZ  sulfasalazine; NSAID  nonsteroidal
antiinflammatory drug; NA  not available.
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Analysis of DNA fragmentation. Demonstration of
DNA laddering on agarose gels was performed as previously
described (20), with some modifications. Briefly, cells were
lysed in Tris–EDTA (TE) buffer containing 0.2% Triton
X-100, pH 8.0. Fragmented DNA was separated from intact
chromatin by microfuging at 14,000 rpm at 4°C for 20 minutes.
The resulting supernatant was treated with 1 mg/ml of protein-
ase K at 37°C overnight, then extracted with phenol–
chloroform–isoamyl alcohol (at a ratio of 25:24:1) 3 times.
DNA was precipitated by the addition of 3 volumes of absolute
ethanol, in the presence of 0.3M sodium acetate, pH 5.2, and
incubated overnight at 20°C and then pelleted by centrifu-
gation at 14,000 rpm at 4°C for 20 minutes. The pellet was
washed twice with 75% ethanol and dissolved in 30 l of TE
buffer containing 10 g/ml of RNase overnight at 37°C. DNA
samples were separated by electrophoresis on 1.8% agarose
gels in the presence of ethidium bromide.
A TUNEL assay was performed as previously de-
scribed (21). Cells were fixed in 1% buffered formaldehyde
(pH 7.4) for 15 minutes on ice, washed in phosphate buffered
saline (PBS), and stored at 4°C in 70% ethanol. Subsequently,
cells were resuspended in 50 l of a solution containing 5 units
of terminal deoxynucleotidyl transferase (Boehringer Mann-
heim, Indianapolis, IN), 2.5 mM COCl2, 0.2M potassium
cacodylate, 25 mM Tris HCl, 0.25 mg/ml bovine serum albumin
(BSA), and 0.5 nM biotin-16-dUTP (Boehringer Mannheim).
Cells were incubated in this solution at 37°C for 30 minutes,
then rinsed in PBS and resuspended in 100 l of staining
solution containing 2.5 g/ml fluorescinated avidin, 4 con-
centrated saline sodium citrate buffer, 0.1% Triton X-100, and
5% (weight/volume) nonfat dry milk. Cells were incubated in
this solution for 30 minutes at room temperature in the dark.
Cells were then rinsed in PBS containing 0.1% Triton X-100
and resuspended in 1 ml of PBS containing 5 g/ml propidium
iodide and 0.1% RNase (Sigma). Green (biotinylated dUTP)
and red (DNA) fluorescence of individual cells were measured
with an Epics Elite Flow Cytometer (Coulter, Hialeah, FL).
Caspase 3 activity. The assay for caspase 3 activity was
based on a previously published method (22). Briefly, cells
were lysed by agitation for 15 minutes in assay buffer (50 mM
HEPES, 100 mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10%
glycerol, 10 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride [PMSF], pH 7.4). The lysates were centrifuged at
16,000g for 10 minutes, and the supernatants were collected.
The caspase 3 substrate Ac-DEVD-AMC (Axxora, San Diego,
CA) was added at a final concentration of 50 M. The assay
was performed in opaque black 96-well plates (OptiPlate-96 F;
PerkinElmer, Boston, MA). The plates were read using a
Fusion-Alpha HT instrument (365-nm excitation filter and
425-nm emission filter; PerkinElmer) for 3 hours.
Western blotting. Five million cells were washed and
suspended in 100 l of lysis buffer (1% sodium dodecyl sulfate
[SDS], 1 mM sodium vanadate, 10 mM Tris [pH 7.6]), and
boiled for 5 minutes. After microcentrifugation at 14,000 rpm
for 10 minutes, supernatants were recovered. The protein
concentration of the lysates was determined with bicinchoninic
acid protein assay reagent (Pierce, Rockford, IL). For caspase
3 immunoblots, cell lysates (10–20 g of protein per lane) were
separated on 15% SDS–polyacrylamide gels under reducing
conditions, transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA), and probed with mouse
monoclonal anti–caspase 3 (clone 19, IgG2a; Signal Transduc-
tion Lab, Lexington, KY) followed by sheep F(ab)2 fragment
horseradish peroxidase–conjugated, anti-mouse immunoglob-
ulin (Amersham, Piscataway, NJ). For poly(ADP-ribose) poly-
merase (PARP) immunoblots, cell lysates (10 g of protein per
lane) were separated on 7.5% SDS–polyacrylamide gels, trans-
ferred to PVDF membranes, and probed with monoclonal
mouse anti-human PARP antibody C2.10 (IgG1; Enzyme
Systems Products, Dublin, CA). Antibody binding was de-
tected with an enhanced chemiluminescence detection system
(Amersham).
Determination of SPHK enzymatic activity and S1P
levels. To measure SPHK activity, cells were washed twice with
cold PBS, centrifuged, and resuspended in 200 l of the buffer
(20 mM Tris buffer, pH 7.4, containing 20% [volume/volume]
glycerol, 1 mM mercaptoethanol, 1 mM EDTA, 1 mM sodium
orthovanadate, 15 mM NaF, 10 g/ml leupeptin and aprotinin,
and 1 mM PMSF). Cells were frozen and thawed 4 times by
transferring from liquid nitrogen to a 37°C water bath. Cell
lysates were centrifuged for 30 minutes at 14,000 rpm/minute.
The buffer was mixed with supernatant that contained 70–
200 g of protein to a final volume of 190 l. The reactions
were started by the addition of 10 l of -32P ATP (2 Ci,
20 mM) and sphingosine–BSA, 50 M final concentration,
containing 100 mM MgCl2. Samples were incubated for 30
minutes at 37°C, and reactions were terminated by the addi-
tion of 20 l of 1N HCl. Lipids were extracted by the addition
of 0.8 ml of chloroform, methanol, and concentrated HCl
(100:200:1 [v/v/v]). Phases were separated by the addition of
240 l of chloroform and 240 l of 2N KCl. The organic
phase was evaporated under N2 and resuspended in 50 l of
chloroform–methanol mixture (at a ratio of 1:2). Lipids were
resolved by thin-layer chromatography on Uniplate silica gel G
(Analtech, Newark, DE) using 1-butanol, methanol, acetic
acid, and water (80:20:10:20 [v/v/v/v]) as solvent. The radio-
active spots corresponding to authentic S1P were located by
standard S1P, which was visualized by charring with cupric
sulfate–phosphoric acid spray. Radioactive SP-1P spots
were quantified with a PhosphorImager (Molecular Dynam-
ics, Fairfield, CT).
To determine S1P levels, 5  106 cells were washed
twice with cold PBS, centrifuged, and resuspended in 500 l of
buffer (138 mM NaCl, 3.3 mM NaH2PO4, 2.9 mM KCl, 1 mM
MgCl2, 1 mg/ml glucose, and 20 mM HEPES [pH 7.4]). Three
milliliters of ice-cold chloroform–methanol (1:2 [v/v]) was
added to the buffer, followed by thorough mixing and sonica-
tion for 30 minutes. Phases were separated by adding 2 ml of
chloroform, 2 ml of 1M KCl, and 100 l 7N NH4OH. The
alkaline bottom phases were used for sphingosine quantifica-
tion. The alkaline upper phases were transferred to new tubes,
and 3 ml of chloroform and 200 l of concentrated HCl were
added. The bottom chloroform phases formed under these
new acidic conditions were evaporated under N2 and used for
S1P quantification, as previously described (23).
Extraction of total RNA and reverse transcription
(RT). Total cellular RNA was extracted using the RNeasy Mini
Kit (Qiagen, Valencia, CA). Briefly, 1  107 LCL cells or
50–100 mg of dissected synovial tissue was placed in 600 l
of lysis buffer containing 4M guanidinium salt and
-mercaptoethanol, and homogenized by using a microultra-
sonic cell disrupter. After the addition of 600 l of 70%
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ethanol, the mixture was loaded onto an RNeasy spin column
and centrifuged for 0.5 minutes at 8,000g. The column was
washed with a buffer containing 70% ethanol and centrifuged
twice. After treatment with DNase I, total RNA was collected
with 50 l of diethyl pyrocarbonate–-treated water and stored
at 70°C. The concentration and purity of RNA were deter-
mined by absorbance at 260 nm and 280 nm. Complementary
DNA (cDNA) was synthesized from 1 g total RNA by using
MultiScribe reverse transcriptase (Applied Biosystems, Foster
City, CA). Negative controls were prepared using all reagents
except the RNA sample or without reverse transcriptase.
RT–polymerase chain reaction (RT-PCR). Exon-
spanning primers specific for SPHK-1, SPHK-2, and -actin
were designed based on published cDNA sequences. The
oligonucleotide sequences were as follows: for SPHK-1, for-
ward 5-TTGAACCATTATGCTGGCTATGAG-3, reverse
5-CAGCAGGTTCATGGGTGACA-3; for SPHK-2, forward
5-TTTGCCCTCACCCTTACATC-3, reverse 5-TTCAG-
AGATCATGGGAAGCA-3; for -actin, forward 5-AGA-
AAATCTGGCACCACACC-3, reverse 5-AGAGGCGTAC-
AGGGATAGCA-3.
Reactions were carried out in PCR Master Mix buffer
(Promega), containing 50 mM Tris HCl (pH 9), 3 mM MgCl2,
400 M dNTPs, and 50 units Taq DNA polymerase. The
reaction mixture contained 22.5 l PCR Master Mix, 2 l of
primers at a concentration of 20 M, 5.5 l cDNA, and 15 l
H2O. PCR incubations were conducted in a programmable
thermal controller (ThermoHybaid, Philadelphia, PA). Each
cycle included denaturation at 94°C for 30 seconds, annealing
at 55°C for 45 seconds, and extension at 72°C for 60 seconds.
The final extension was performed at 72°C for 5 minutes.
Thirty cycles were performed for PCR tubes containing -actin
template, whereas 38 cycles were used for amplifying SPHK.
The DNA was separated on a 1.5% agarose gel. Gels were
stained for 20 minutes in Tris–borate–EDTA buffer containing
0.5 g/ml ethidium bromide, destained for 30 minutes, exam-
ined on an ultraviolet transilluminator, and photographed with
a Bio-Rad gel scanner (Bio-Rad, Hercules, CA).
Real-time quantitative PCR. Reactions were carried
out in 2 PCR Master Mix (Applied Biosystems) in a total
volume of 50 l containing 5 l (2 l for -actin) of cDNA,
0.4 M of each PCR primer, 0.2 M of TaqMan probe
with passive reference, and 25 l of PCR Master Mix. SPHK
and -actin genes were amplified in separate tubes in
duplicate. The amplification parameters were 50°C for
2 minutes, 95°C for 10 minutes, and 50 cycles at 95°C for
15 seconds and at 60°C for 1 minute. The following exon-




forward 5-GACGGGCTGCTCCATGAG-3, reverse 5-
TTCACAGCTTCCTCCCAGTCA-3, probe 5-FAM-TGCT-
GAACGGGCTCCTAGATCGCC-TAMRA-3; for -actin,
forward 5-AGAAAATCTGGCACCACACC-3, reverse 5-
AGAGGCGTACAGGGATAGCA-3, probe 5-FAM-ACC-
GCGAGAAGATGACCCAGATC-TAMRA-3.
Emission fluorescence from individual PCR tubes at
each cycle was monitored using an iCycler (Bio-Rad). Data
were collected, consisting of the threshold cycle values corre-
sponding to the PCR cycle number at which fluorescence was
detectable above an arbitrary threshold, based on baseline data
within cycles 3–15. The threshold was determined to ensure
that the threshold cycle values were obtained in the exponen-
tial phase of PCR, during which no rate-limiting components
are expected. To construct a standard curve, cDNA was
synthesized from total RNA extracted from cell culture and
then diluted in 5 steps, 2–32 times. A standard curve of
threshold cycle values against the log value of cDNA was
generated for both SPHK and -actin. The PCR product was
checked on 1% agarose gels to ensure there was no amplifi-
cation from genomic DNA. The relative concentrations of
SPHK and -actin were obtained from the standard curve, and
the ratios of SPHK normalized against -actin were calculated.
Inhibition of SPHK gene expression by small inter-
fering RNA (siRNA). SPHK-1 and SPHK-2 gene expression
in LCLs was knocked down by using specific siRNA oligo-
nucleotides. The siRNA for the SPHK-1 gene was a 21-nucleo-
tide siRNA directed at a target sequence 70 nucleotides
downstream of the start codon (5-AAGGGCAAGGCC-
TTGCAGCTC-3), based on a published report (24).
The siRNA for the SPHK-2 gene was a 21-nucleotide siRNA
directed at a target sequence 645 nucleotides downstream of
the start codon (5-AACCTCATCCAGACAGAACGA-3),
which was designed using Qiagen siRNA software.
Cells were transfected with either the 21-nucleotide
duplexes for SPHK (2 g siRNA/sample) for gene silencing or
a 21-nucleotide scrambled siRNA as negative control (Qia-
gen), or an enhanced green fluorescent protein vector (Amaxa
Biosystems, Gaithersburg, MD) for monitoring the transfec-
tion rates using nucleofection technology (Amaxa Biosystems).
Briefly, 107 cells were resuspended in a 100-l solution from
the Nucleofector Kit T (Amaxa Biosystems), following the
manufacturer’s guidelines for cell line transfection, using the
provided cuvette and nucleofected with a Nucleofector appa-
ratus. After being electroporated, the cells were immediately
transferred into a culture flask containing culture medium
prewarmed to 37°C. The cells were then cultured for 96 hours
before analyzing the gene-silencing effects. The mRNA levels
were measured by quantitative real-time PCR analysis.
RESULTS
As shown in Figure 1A, LCLs from normal
controls died efficiently after exposure to the agonist
anti-Fas antibody CH-11. In contrast, LCLs from pa-
tients with RA showed markedly reduced cell death.
Disease susceptibility in RA is closely associated with
HLA–DRB1 alleles encoding a shared epitope (SE) in
the third hypervariable region of the HLA–DR chain
(25). Of note, we did not find any relationship between
the presence of either 1 or 2 SE-encoding DRB1 alleles
and resistance to Fas-mediated cell death in the RA
group. Similarly, no resistance to Fas-mediated cell
death was observed in healthy control subjects express-
ing either 1 or 2 SE alleles.
In order to more accurately assess the relative
contribution of genetic versus nongenetic factors, we
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Figure 1. A, Resistance of rheumatoid arthritis (RA) lymphoblastoid cell lines (LCLs) to Fas-mediated cell death. LCLs from 15 healthy controls
() and 15 patients with RA (E) were incubated with anti-Fas antibody. The percentage of cell death was determined at different time points
thereafter, using the MTS method. B, Comparison of cell death in RA versus other autoimmune diseases. Fas-mediated cell death was determined
in LCLs from 8 patients with systemic lupus erythematosus (SLE), 10 patients with juvenile RA (JRA), 5 patients with insulin-dependent diabetes
mellitus (IDDM), 3 patients with autoimmune thyroiditis, 15 patients with RA, and 15 normal (NL) controls. The percentage of cell death 20 hours
after anti-Fas antibody treatment was determined by the MTS method. NS  not significant. C, Determination of anti-Fas antibody–mediated DNA
fragmentation by the TUNEL assay in LCLs from 6 normal controls and 5 patients with RA. Values are the mean  SD. D, Determination of
anti-Fas antibody–mediated DNA fragmentation in LCLs from 4 normal controls and 4 patients with RA by agarose gel electrophoresis. Cells were
treated with either anti-Fas antibody (CH-11) or an isotype-matched control antibody (TEPC-183), as described in Patients and Methods.   P 
0.05.
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conducted experiments on a panel of 20 LCLs derived
from 10 RA-discordant monozygotic twin pairs (Table
2). Fas-mediated cell death was significantly lower in the
RA twin group compared with that in the healthy twin
group (mean  SD 12.9  2.0% and 29.4  3.3%,
respectively; P  0.0006). In all but 1 pair of twins,
resistance to Fas-mediated cell death was seen in the RA
twin but not in the healthy twin (P  0.005). Thus, we
concluded that resistance to Fas-mediated cell death in
RA represents a disease-related defect rather than a
genetically determined defect.
Resistance to Fas-mediated cell death was ob-
served in 22 of the 23 RA patients studied, independent
of their age, sex, disease duration, the presence of
rheumatoid factor, erosions, or rheumatoid nodules, and
irrespective of their drug treatment (Table 1). The
resistance was not observed in other autoimmune dis-
eases (Figure 1B). For example, the mean  SD per-
centage of cell death induced by anti-Fas antibodies in
LCLs from patients with JRA (21.5  2.1%), SLE
(23.5  5.0%), IDDM (26.3  8.2), and autoimmune
thyroiditis (28.2  4.4%) was significantly higher than
that in the RA group (12.9  2.0%) (P  0.003, P 
0.01, P  0.01, and P  0.05, respectively). No statisti-
cally significant differences were found between Fas-
mediated cell death in the healthy group and any of the
control autoimmunity groups, or among the different
autoimmunity groups (Figure 1B).
Resistance of RA LCLs to Fas-induced cell death
was attributable to failed apoptosis, as demonstrated by
DNA fragmentation data. In control LCLs, Fas ligation
triggered DNA fragmentation as determined by the
TUNEL assay (Figure 1C) and by analysis of DNA
laddering by agarose gel electrophoresis (Figure 1D). In
contrast, RA LCLs did not show evidence of DNA
fragmentation. RA LCLs were not innately resistant to
programmed cell death, because they displayed some,
albeit delayed, Fas-mediated caspase 3 activation (Fig-
ure 2A). Additionally, LCLs from patients with RA and
controls were equally sensitive to apoptosis following
treatment with staurosporine (data not shown).
Figure 2. Fas-mediated signaling in RA LCLs. A, LCLs from 7
patients with RA and 6 normal controls were incubated with the
anti-Fas antibody CH-11 over time, and caspase 3 activation was
determined. Results represent the increase in caspase 3 activity above
baseline levels. Values are the mean  SD. B and C, Western blot
analyses with either anti–caspase 3 or anti–poly(ADP-ribose) polymer-
ase (anti-PARP) were performed on LCLs at different time points
following activation with the anti-Fas antibody CH-11. Representative
LCLs from 1 patient with RA and 1 healthy control are shown. Similar
patterns were obtained in all 4 pairs of RA and normal cell lines tested
(results not shown).   P  0.02. See Figure 1 for other definitions.









1 0401/1201 33 18
2 0401/1104 41 19
3 0101/0301 21 13
4 0101/1302 26 9
5 0401/0401 29 11
6 0404/1401 31 14
7 0401/0701 27 0
8 0401/0701 23 9
9 0401/0401 13 22
10 0405/11 50 14
* RA  rheumatoid arthritis.
† Mean  SD 29.4  3.3%.
‡ Mean  SD 12.9  2.0%; P  0.0006 versus healthy twin.
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Resistance to Fas-mediated apoptosis in RA
LCLs could not be attributed to reduced Fas receptor
density, because similar levels of Fas expression were
detected by flow cytometry on LCLs from normal indi-
viduals and patients with RA. Additionally, LCLs from
controls and patients with RA expressed similar levels of
CD30 and CD40 surface proteins (data not shown).
The findings described above suggest that an
intracellular mechanism may be responsible for the
observed resistance to apoptosis. Examination of the Fas
pathway in RA LCLs revealed impaired signaling. Fig-
ure 2A compares caspase 3 activation following Fas
ligation in LCLs from patients with RA and normal
controls. As can be seen, although RA cells displayed
some activation, it was markedly delayed compared with
that in normal cells (P  0.02). Impaired Fas-mediated
signaling could also be demonstrated by the absence of
signature proteolytic cleavage products of caspase 3
(Figure 2B) and poly (ADP-ribose) polymerase (PARP)
following Fas ligation (Figure 2C). Thus, the resistance
of RA lymphocytes to Fas-mediated apoptosis was asso-
ciated with impaired signal transduction.
The finding of diminished and delayed caspase 3
activation in RA cells suggests that the Fas pathway is
intrinsically intact but may be subjected to inhibition by
an extrinsic regulatory mechanism. It has been previ-
ously proposed that the efficiency of Fas-mediated cell
death signaling may be regulated by SPHK via its
antiapoptotic product, S1P (26). We therefore assessed
the role of SPHK. As can be seen in Figure 3A, RA cells
displayed markedly increased SPHK enzyme activity
compared with control cells (P  0.02). The increased
SPHK enzymatic activity in RA LCLs was associated, as
expected, with increased intracellular levels of S1P (Fig-
ure 3B).
We next investigated whether constitutively ac-
tive SPHK plays a role in the observed resistance of
RA LCLs to Fas-mediated apoptosis. To that end,
we first used a pharmacologic approach. Preincubation
of cells with the SPHK competitive inhibitor N,N-
dimethylsphingosine reversed the resistance of RA
LCLs to Fas-mediated apoptosis to near-normal levels
(Figure 3C). A similar effect was observed with another
SPHK-specific inhibitor, DL-threo-dihydrosphingosine
(data not shown).
The 2 known SPHK isoenzymes are SPHK-1 and
SPHK-2. Transcripts for both isozymes are expressed in
LCLs (Figure 4A). To quantify SPHK mRNA expres-
sion levels, we performed real-time PCR analyses on
LCLs from 10 pairs of RA-discordant monozygotic
twins. In 7 of the 10 twin pairs, SPHK-1 mRNA levels
were higher in the RA twin compared with the healthy
twin. In contrast, SPHK-2 mRNA levels were clearly
higher in the RA twin in only 2 of the 10 pairs (Figure
4B). The mean  SD SPHK-1 mRNA expression levels
were 6.31  1.58–fold higher in the RA twin cells
compared with their healthy cotwins (P  0.008 by
Mann-Whitney U test).
To investigate whether SPHK is responsible for
aberrant Fas signaling, RA LCLs showing increased
SPHK-1 and SPHK-2 transcripts and resistance to Fas
signaling were transfected with siRNA oligonucleotides
designed for either SPHK-1 or SPHK-2. Transfection
with these siRNA oligonucleotides resulted in 52% and
57% suppression of SPHK-1 and SPHK-2 mRNA ex-
pression, respectively, as determined by real-time PCR
(data not shown). As shown in Figure 4C, LCLs trans-
fected with SPHK-1 siRNA showed markedly enhanced
Figure 3. Role of sphingosine kinase (SPHK; SK) in resistance to
Fas-mediated apoptosis. A, Comparison of constitutive SPHK activity
in lymphoblastoid cell lines (LCLs) from 9 patients with rheumatoid
arthritis (RA) and 11 normal (NL) controls. Boxed image shows a
representative PhosphorImager display of the SPHK activity assay in 1
patient with RA (right) and her healthy twin sister (left). B, Constitu-
tive levels of sphingosine 1-phosphate (S1P) in LCLs from 8 normal
controls and 5 patients with RA. C, Reversal of RA LCL resistance to
Fas-mediated apoptosis by N,N-dimethylsphingosine (DMS). Fas-
mediated apoptosis was determined in LCLs from 6 patients with RA
and 5 healthy controls, using the MTS method. Values are the mean 
SD.   P  0.02.
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Fas-mediated caspase 3 activity (P  0.01). In con-
trast, transfection with an SPHK-2–specific siRNA oligo-
nucleotide had no effect (Figure 4C). Thus, we con-
cluded that SPHK-1 overexpression is responsible for
the observed resistance to Fas-mediated signaling.
Finally, in order to assess the relevance of these
findings to RA, we used real-time PCR to measure
SPHK-1 and SPHK-2 transcript levels in synovial tissues
from 14 patients with RA and 9 patients with OA
(Figures 4D and E). A striking difference between the 2
diseases was observed. In RA, SPHK-1 was more abun-
dantly expressed than SPHK-2 (P  0.02), while the
opposite relationship was found in OA (P  0.0004).
The ratio of the SPHK-1 to SPHK-2 transcript expres-
sion level was 86.6-fold higher in RA than in OA (mean
8.66 versus 0.1; P  0.00008 by Mann-Whitney U test).
DISCUSSION
The findings reported here demonstrate an im-
pairment in Fas-mediated cell death signaling in RA
LCLs and strongly implicate overactivity as a candidate
mechanism. The characterization of biochemical mech-
anisms involved in cell death signaling requires an
abundant supply of large numbers of homogeneous cells,
which often is not feasible in human research. This
technical caveat has slowed research into the mecha-
nisms of B lymphocyte apoptosis in RA, due to the
scarcity of peripheral B cells in this disease (15,16). In
order to overcome this obstacle, we used immortalized B
cell lines in this study. Test and control B cell lines were
maintained under identical tissue culture conditions and
expressed identical phenotypes. Therefore, as opposed
to data obtained with primary cells, the aberrations
observed here represent a genuine qualitative defect
rather than a reflection of cell frequency–dependent
phenomena. Additionally, by using RA-discordant
monozygotic twin pairs, the possibility that genetic or
demographic disparities are responsible for the differ-
ences between patients and controls has been effectively
excluded.
The use of LCLs has been previously proven to
be instrumental in uncovering important pathogenic
mechanisms in other diseases, such as hypertension,
glycogen and lipid storage diseases, chronic granuloma-
tous disease, hematologic disorders, and solid tumors
(27–33). One illustrative example is essential hyperten-
sion. Although LCLs have no relevance to blood vessel
physiology, their use enabled the discovery of a
G-protein signaling aberration in hypertension (27).
Analogously, the relevance of LCLs to pannus pathology
may be uncertain; however, the data presented here
clearly demonstrate that those cells express a disease-
specific signaling aberration and thus provide an insight
into a potential pathogenic mechanism and a strong ra-
Figure 4. Identification of the sphingosine kinase (SPHK) isozyme. A,
Reverse transcription–polymerase chain reaction (RT-PCR) analysis
of SPHK-1 and SPHK-2. Lane 1, Molecular size markers; lane 2,
positive control (human lung); lane 3, negative control (RNA without
RT); lanes 4–9, lymphoblastoid cell lines (LCLs) from healthy twins
(lanes 4, 6, and 8) and their respective cotwins with rheumatoid
arthritis (RA) (lanes 5, 7, and 9). B, Real-time PCR analysis of Sphk1
and Sphk2 expression in 10 twin pairs. SPHK abundance was normal-
ized to the -actin expression level for each LCL. The data shown
represent the ratio of SPHK abundance in the RA twin line relative to
its healthy cotwin line. Values 1.0 indicate higher, and values 1.0
indicate lower SPHK mRNA expression in the RA twin relative to the
healthy cotwin. C, Reversal of the Fas-mediated signaling aberration
with SPHK-specific small interfering RNA (siRNA) oligonucleotides.
LCLs from patients with RA were transfected with siRNA oligonucleo-
tides specific for Sphk1 or Sphk2. Control cultures were subjected to
mock transfection. After 96 hours in growth culture, LCLs were
incubated overnight with anti-Fas antibodies, and caspase 3 activity
was determined. D, Real-time PCR analysis of Sphk1 and Sphk2
mRNA expression levels in synovial tissue from 14 patients with RA
and 9 patients with osteoarthritis (OA). E, Ratio between Sphk1 and
Sphk2 in synovial tissue from 14 patients with RA and 9 patients with
OA. Values are the mean and SD. NS  not significant.   P 
0.00008.
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tionale for future exploration of the role of that aberra-
tion in RA.
Although genetic factors are known to play a role
in RA susceptibility, the concordance rate of this disease
in monozygotic twins has been estimated to be 15%
(34). The surprisingly low concordance rate suggests that
nongenetic events may be necessary to trigger disease
onset in genetically susceptible individuals. In this study,
we demonstrated that resistance to Fas-mediated apo-
ptosis is a disease-related, rather than a genetically
determined, phenomenon. No association with particu-
lar HLA–DRB1 alleles could be found in unrelated
subjects, indicating that the defect is not merely a
consequence of the presence of the SE in RA. Further-
more, experiments with disease-discordant monozygotic
twins indicate that the aberration is not determined
genetically. These findings and the fact that the aberra-
tion is disease-specific strongly suggest that the signaling
impairment observed here is directly relevant to the
pathogenesis of RA.
Aberrations in Fas-mediated cell death signaling
in RA have been previously demonstrated in T cells and
in synoviocytes (for review, see ref. 3), while involvement
of the Fas pathway in RA B cells is basically unknown. In
murine autoimmune models, Fas signaling aberrations
in B cells have been shown to play a major role in
autoantibody production (for review, see ref. 35). Mice
in which Fas expression is diminished (lpr/lpr) or in
which its signaling is inefficient (lprcg/lprcg) develop
autoantibodies. Although both T and B cells are affected
in those genetic models, B cells contribute an autono-
mous effect to the autoimmune phenotype, independent
of the T cell effect (36,37), suggesting that the Fas
pathway plays a role in the maintenance of B cell
tolerance, and that Fas-resistant B cells play a key role in
autoimmunity. Similar to those models, the data pre-
sented here implicate Fas pathway impairment in RA B
lymphocytes. Unlike the defects observed in those ex-
perimental models, however, our data indicate that in
RA the Fas pathway is intrinsically intact but is inhibited
by an extrinsic regulatory mechanism. Of note, inhibi-
tion of an otherwise intact Fas pathway has been shown
to lead to autoimmunity in heterozygous pten/ mutant
mice (38). Thus, impairment of Fas-mediated death
signaling, either at the receptor–ligand level or further
downstream, can lead to a similar end result of autoim-
munity.
It is worth mentioning that cell accumulation in
RA has a predilection for the joints. Therefore, the
resistance of peripheral blood–derived cell lines ob-
served here suggests that circulating lymphocytes pos-
sess latent resistance to Fas-mediated cell death. Upon
activation, those cells may preferentially home to the
joints and accumulate there due to the unique synovial
microenvironment, which allows resident synoviocytes
and homing lymphocytes to best exercise their abnormal
survival tendencies in a codependent manner (9–12). Re-
cent studies have identified BAFF as an important factor in
synovial B cell survival (39) and autoimmunity (40).
Our data directly implicate SPHK overactivity as
the underlying mechanism of impaired Fas-mediated
death signaling in RA. We demonstrate here that RA
LCLs display increased constitutive SPHK enzymatic
activity, and that the majority of RA LCLs, as well as
RA synovial tissues, have increased mRNA expression
of SPHK-1. It should be cautioned, however, that due to
the heterogeneous cellular composition of synovial tis-
sues, the increased SPHK-1 transcripts reported here
cannot be attributed exclusively to B cells. Further
studies, using advanced methodologies such as in situ
hybridization or laser capture microdissection, will be
required to resolve this question.
Blocking SPHK activity with competitive inhibi-
tors or knocking down SPHK-1 mRNA expression re-
stored Fas-mediated death signaling. These findings are
consistent with the current understanding of SPHK
function (41–44). Enhanced SPHK activity promotes
cell survival in many cell systems, including lymphocytes,
in which SPHK has been shown to inhibit ceramide- and
Fas-induced cell death (41). Consistent with our data, of
the 2 known isozymes, SPHK-1 has been consistently
shown to be a potent inhibitor of apoptosis, while
SPHK-2 lacks that capability and has actually been
reported to suppress cell growth and enhance apoptosis
in certain cell systems (42,43). Importantly, SPHK has
been previously implicated in inflammatory arthritis,
because the locus containing Sphk1 (at the telomeric
region of chromosome 10) has been identified as an
arthritis susceptibility region in rats (44).
It is worth noting that SPHK-1 overactivity and
resistance to Fas-mediated death could be found in
LCLs long after their isolation. This finding indicates
that the observed aberration represents a genuine intrin-
sic defect rather than a transient response to cytokines,
growth factors, medications, or other influences by the
rheumatoid milieu. These findings suggest a lasting
imprint of B cells derived from patients with RA as
compared with controls. Among the candidate explana-
tions that need to be considered are the following:
different EBV infection rates between RA and control B
cells (45), or an effect of preexistent triggers of B cell
survival that may have led to lasting functional repro-
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gramming in these cells. A third explanation for this
nongenetic functional aberration involves epigenetic
mechanisms. In recent years, there has been growing
interest in the role of posttranscriptional events and
epigenetic mechanisms in disease pathogenesis. Because
SPHK-1 gene expression is epigenetically modified by a
differentially methylated region at the 5 end of an
adjacent GpC island (46), it is tempting to speculate that
this mechanism might be involved in the aberration
described in the current report.
The biologic effects of SPHK are attributable to
its product, S1P. This sphingolipid metabolite displays
both intracellular and extracellular activities and has
been shown to play a role in diverse processes that may
be relevant to RA pathogenesis, including angiogenesis,
cell migration, cell growth, and cell differentiation (for
review, see ref. 26). Of particular relevance to this study,
S1P has been previously shown to suppress cell death
induced by Fas ligand (47). The mechanism of the
S1P-mediated antiapoptotic effect is incompletely un-
derstood. Although the relative role of S1P as an
intracellular second messenger versus an extracellular
paracrine or autocrine agonist is a matter of ongoing
debate, its potency as an inhibitor of Fas-mediated death
signaling is well documented. At nanomolar concentra-
tions, S1P triggers a cell survival pathway, which involves
activation of ERK, NF-B, and phosphoinositide
3-kinase (PI 3-kinase), as well as inhibition of JNK, p38,
Bax, and caspase 3 (for review, see ref. 48). Our own
data indicate that S1P survival signaling in LCLs involves
activation of PI 3-kinase, inhibition of JNK, and suppres-
sion of executioner caspases via a Gi protein–coupled
receptor mechanism (Tan S-Y, et al: unpublished obser-
vations).
S1P exerts potent effects that regulate the im-
mune system through receptor-mediated survival signal-
ing, chemotaxis, proliferation, and cytokine production
(for review, see ref. 17). One of the most notable
immune effects of S1P is its rapid receptor-mediated
regulation of immune cell migration (49). S1P is now
considered central in the physiologic immune response,
and aberrations in its function could likely lead to
immunopathologic processes and disease. In this con-
text, it is noteworthy that a phosphoryl metabolite of the
sphingosine analog FTY720, a promising new immuno-
suppressive prodrug (50), has been shown to prevent
experimental autoimmunity models, including inflam-
matory arthritis in rats, presumably by inhibiting lym-
phocyte egress from the lymph node to the periphery
(51).
In conclusion, we report a heretofore unknown
disease-associated dysregulation of SPHK, which in-
hibits Fas-mediated cell death signaling in RA. The
reversibility of the aberration suggests that further
characterization of the molecular mechanism(s) in-
volved could help in identifying targets for therapeutic
intervention in RA.
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